He’s a musician and a clothing designer. He’s a published author. He’s a professional scuba-diving instructor — and he has an intense passion for underwater shark photography. In fact, Noah Greenspan is anything but your typical New York pulmonary physical therapist. Since 1998, Greenspan has been running the Pulmonary Wellness…
Talking about lung transplantation is frightening. It was scary when it was initially introduced following my diagnosis nearly three years ago, and it continues to be difficult to talk about. This is despite all that I’ve been through with my disease progression over the years. Recently, I talked…
A protein called cadherin-11 (CDH11) ties together macrophages and myofibroblasts in an “eternal hug” in the lungs of idiopathic pulmonary fibrosis (IPF) patients, promoting a profibrotic environment, a study shows. Therapies that target CDH11 and break the “hug” between the two cell types may help stop this profibrotic process. The…
A large, multi-center clinical trial testing the proton pump inhibitor omeprazole as a therapy for cough in idiopathic pulmonary fibrosis (IPF) patients seems achievable and justified, according to results of a single-center pilot trial. The pilot study also suggests the need to screen large patient numbers and monitor adverse side…
It’s no secret that I love to travel. Upon receiving my idiopathic pulmonary fibrosis (IPF) diagnosis in 2016, my biggest fear was that this cruel lung disease would take away my physical ability to explore the world. While IPF has certainly changed how I travel, I am grateful…
The tolerability and safety of Ofev (nintedanib) and Esbriet (pirfenidone) treatments in a small group of patients with idiopathic pulmonary fibrosis (IPF) in South England were found to be similar to real-world data. The research confirmed the safety of both IPF therapies. The retrospective study, “South-West…
All pulmonary fibrosis patients require supplemental oxygen as our disease progresses. As scarring in our lungs worsens, we need extra oxygen to stay alive. Starting using oxygen I was shocked when my doctor told me that I needed to use supplemental oxygen, which involves rolling a tank around…
Synairgen announced it successfully completed three-month toxicity studies on LOXL2 (lysyl oxidase like 2) inhibitor candidates for treating idiopathic pulmonary fibrosis (IPF). The LOXL2 program, developed in collaboration with Pharmaxis, may move into Phase 2 trials. Synairgen and Pharmaxis began their collaboration in 2015 to develop…
There is no question that living with pulmonary fibrosis is exhausting for patients and caregivers alike. Those who may not have any experience with PF might assume that it is only a physically limiting disease. I would have thought the same before my idiopathic pulmonary fibrosis (IPF) diagnosis in…
Bridge Biotherapeutics’ investigational therapy candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA). According to the company, BBT-877 is a best-in-class autotaxin (ATX) inhibitor, and a potential anti-inflammatory and anti-fibrotic treatment for IPF. Studies have shown…
Get regular updates to your inbox.
